Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study

Immune-related adverse events (irAEs) are very prevalent when treating patients with ipilimumab and nivolumab in combination, and 30–40% of patients discontinue the treatment for this reason. It is of high clinical relevance to investigate the consequences of discontinuing the treatment early since...

Full description

Bibliographic Details
Main Authors: Morten Fink, Anders Schwartz Vittrup, Lars Bastholt, Inge Marie Svane, Marco Donia, Adam A. Luczak, Christina H. Ruhlmann, Louise Mahncke Guldbrandt, Ulrich Heide Koehler, Mette Lerche Winther, Eva Ellebaek, Charlotte Aaquist Haslund, Henrik Schmidt
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
ipilimumab
nivolumab
melanoma
immune-related adverse events
DAMMED
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/13/21/5550

Internet

https://www.mdpi.com/2072-6694/13/21/5550

Similar Items